Keyphrases
Acute Lymphoblastic Leukemia
100%
Childhood Acute Lymphoblastic Leukemia
51%
Minimal Residual Disease
25%
High Risk
22%
Methotrexate
19%
Tolfenamic Acid
17%
Group Studies
17%
Complete Remission
17%
Children's Oncology Group
16%
Acute Myeloid Leukemia
15%
Pediatric Oncology
14%
L-asparaginase
14%
Pancreatic Cancer
11%
Clinical Trials
11%
Leukemia
11%
Remission
11%
Event-free Survival
11%
Prednisone
10%
Chemotherapy
10%
Precursor B-cell Acute Lymphoblastic Leukemia
10%
Marrow
9%
Ara-C
9%
Pediatric
9%
Relapse Risk
9%
Colorectal Cancer
9%
Remission Induction
9%
Risk Factors
8%
Texas
8%
Childhood Leukemia
8%
High-dose Methotrexate (HD-MTX)
8%
IKZF1
8%
Improved Outcomes
8%
Etoposide
8%
Working Diagnosis
8%
United States
7%
Cytosine Arabinoside
7%
B-cell Acute Lymphoblastic Leukemia (B-ALL)
7%
Combination Chemotherapy
7%
Gastrointestinal Cancer
7%
Leukemia Patients
7%
T Cells
7%
Type 2 Diabetes Mellitus (T2DM)
7%
B Cells
7%
Curcumin
7%
VP16
6%
Total Therapy
6%
Prognostic Factors
6%
Standard Risk
6%
Small Molecules
6%
Obesity
6%
Antiproliferative Activity
6%
Tumor
6%
Bone Marrow
5%
Secondary Acute Myeloid Leukemia (sAML)
5%
Flow Cytometry
5%
Confidence Interval
5%
Colon Cancer
5%
Survivin
5%
Egypt
5%
Clinical Utility
5%
Pediatric Acute Lymphoblastic Leukemia
5%
Survival Rate
5%
Immunogenicity
5%
Liver Cancer
5%
Cranial Irradiation
5%
Overall Survival
5%
Cell Lymphoma
5%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Lymphoblastic Leukemia
65%
Methotrexate
27%
Remission
26%
Malignant Neoplasm
22%
Tolfenamic Acid
18%
Chemotherapy
17%
Leukemia
16%
Clinical Trial
15%
Cytarabine
15%
Childhood Cancer
12%
Minimal Residual Disease
12%
Diseases
12%
Acute Myeloid Leukemia
11%
Vincristine
11%
Pancreas Cancer
9%
Immunotherapy
9%
Prednisone
8%
Intrathecal
8%
Colorectal Carcinoma
8%
Curcumin
7%
Etoposide
7%
Infection
7%
Event Free Survival
7%
Digestive System Cancer
6%
Lymphatic Leukemia
6%
Maturity Onset Diabetes of the Young
6%
Teniposide
6%
Asparaginase
6%
Biological Marker
5%
Colon Carcinoma
5%
Survivin
5%
Survival Rate
5%
Immunogenicity
5%
Acute Leukemia
5%
Medicine and Dentistry
Acute Lymphoblastic Leukemia
73%
Minimal Residual Disease
22%
Pediatrics
16%
Methotrexate
15%
Leukemia
13%
Oncology
13%
Malignant Neoplasm
13%
Childhood Cancer
12%
Acute Myeloid Leukemia
12%
Cytarabine
11%
Diseases
10%
Immunotherapy
10%
Event Free Survival
8%
Clinical Trial
8%
Infection
7%
Spontaneous Remission
7%
Precursor
6%
Leukocyte
6%
Colon Carcinoma
6%
Etoposide
6%
Colorectal Carcinoma
5%
Survival Rate
5%
Lymphoid Leukemia
5%
Prognostic Factor
5%
Maturity Onset Diabetes of the Young
5%
Leukemia in Children
5%